Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0606 • ACR Convergence 2025
Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts
Arielle Mendel¹, Nathalie Amiable², Yvan St-Pierre³, Sasha Bernatsky⁴, Ines Colmegna⁵, Michaël Desjardins⁶, Louis-Pierre Grenier⁷, Fares Kalache⁸, Christian Pineau⁹, Chantal Sauvageau¹⁰, Evelyne Vinet⁴ and Paul Fortin¹¹, ¹McGill University Health Centre, Montréal, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Centre Hospitalier de l'Université de Montréal (CHUM)), Montreal, QC, Canada, ⁷Montreal General Hospital, Montréal, QC, Canada, ⁸McGill University Health Center, Montreal, QC, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Institut national de santé publique du Québec, Quebec City, QC, Canada, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Herpes Zoster (shingles) is a common preventable adverse event in SLE. In Quebec, Canada, the Recombinant Zoster Vaccine (RZV) became free of charge for…
Abstract Number: 0839 • ACR Convergence 2025
Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking
Qiuyu Jing¹, Qiang Li², Chiu Wai Shirley Chan³, Weixin Chen⁴, Fung Yu Nick choi⁴, Iris Tang⁵, Chak Sing Lau⁶, Heidi Ling⁶, Jason Wong⁷ and Philip Li², ¹Center for Oncology & Immunology, Hong Kong, Hong Kong, ²Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ⁶The University of Hong Kong, Hong Kong, Hong Kong, ⁷School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hing Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), lacks reliable non-invasive biomarkers for early detection and monitoring. This study investigates plasma…
Abstract Number: 0388 • ACR Convergence 2025
A Scoping Review of Outcomes of Adults With Childhood-Onset Systemic Autoimmune Rheumatic Diseases
Michael Moore¹, Kaien Gu², Carol Cooke¹, Annaliese Tisseverasinghe¹ and Lily Lim¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) include systemic lupus erythematous (SLE), idiopathic inflammatory myositis (IIM), systemic sclerosis (SSc), Sjögren syndrome (SS), and systemic vasculitis (SV).…
Abstract Number: 0151 • ACR Convergence 2025
Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
Ghassan Makhoul¹, Aziz-ur-Rahman Khalid², Islam Rajab¹, Hasan Munshi¹, Emmanuel Olumuyide³, MD Walid Akram Hussain¹, Aqsa Sorathia¹, Reshma John¹, Ahmed Huzien¹, ivan Mercado¹, Nargis Mateen⁴ and Robert Lahita², ¹St. Josephs University Medical Center, Paterson, ²St. Josephs University Medical Center, Wayne, NJ, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Paterson, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with high morbidity and mortality. The impact of the COVID-19 pandemic on SLE-related deaths…
Abstract Number: 2460 • ACR Convergence 2025
Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Pablo Martínez Calabuig¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Juan José Lerma Garrido⁴, Isabel Martínez Cordellat⁴, Isabel Balaguer Trull⁴, Berta Gómez Correas⁴ and Cristina Campos Fernández³, ¹Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ²Hospital General Universitario, Valencia, Spain, ³Hospital General de Valencia, Valencia, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multisystem involvement and fluctuating activity. Biologic therapies such as Belimumab, Anifrolumab, and Rituximab offer…
Abstract Number: 2649 • ACR Convergence 2025
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Bernard Rubin², Mohan Purushothaman², Wade DeJager³, Susan Macwana⁴, Joel Guthridge⁴, Stan Kamp⁴, Nancy Redinger⁴, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yangfen Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane Kamen⁸, Jill Buyon⁹, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Medical University of South Carolina, Johns Island, SC, ⁹NYU Grossman School of Medicine, New York, NY
Background/Purpose: Immune dysregulation propels systemic lupus erythematosus (SLE) pathogenesis. Capturing it as lab-based screening tests could help prioritize SLE patients for early intervention and proactive…
Abstract Number: 2572 • ACR Convergence 2025
Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
Hunter Sporn¹, Roshni Parulekar-Martins¹, Haopeng Wang¹, Xinran Yu¹, Jeong Yee², Youngmin Kim³, Jing Cui⁴ and Karen H. Costenbader⁵, ¹Massachusetts Institute of Technology, Boston, ²Sungkyunkwan University, Suwon, MA, South Korea, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Timely diagnosis and clinically meaningful stratification of systemic lupus erythematosus (SLE) remain major unmet needs. Existing risk models rely on limited genetic or lifestyle…
Abstract Number: 2459 • ACR Convergence 2025
Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Milena Delai¹, Rachel Simon¹, Eduardo Mantovani Cardoso² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, ³Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) plays an important role in the immunomodulation of Systemic Lupus Erythematosus (SLE), reducing the risk of flares and overall mortality. However, long-term…
Abstract Number: 2442 • ACR Convergence 2025
Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
Danae-Mona Nöthling¹, Kirill Anoshkin¹, Panagiotis Garantziotis¹, Laura Bucci¹, Tobias Rothe², Jule Taubmann³, Futoshi Iwata¹, Melanie Hagen¹, Andreas Wirsching¹, Simon Völkl⁴, Fabian Müller⁵, Aline Bozec¹, Andreas Mackensen⁶, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵University Hospital of Erlangen, Erlangen, Germany, ⁶Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by aberrant B cell activation and autoantibody production. CD19-targeted chimeric antigen receptor (CAR) T-cell therapy induces a short,…
Abstract Number: 2423 • ACR Convergence 2025
Clinical and Sociodemographic Factors Associated with Diagnostic Delays in Pediatric Lupus Patients
Michaela Harter¹, Rebecca Hetrick², James Slaven³ and Martha Rodriguez⁴, ¹Indiana University School of Medicine, Indianapolis, IN, ²Indiana University School of Medicine, Zionsville, IN, ³Indiana University School of Medicine, Indianapolis, ⁴Riley Hospital For Children At Indiana University, Carmel, IN
Background/Purpose: Early recognition and treatment of juvenile systemic lupus erythematosus (jSLE) improves outcomes and prevents disease-related mortality. This study examines the contributions of clinical factors…
Abstract Number: 2407 • ACR Convergence 2025
Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
Jorge Juan Fragío Gil¹, Roxana González Mazario², Pablo Martínez Calabuig³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Isabel Martínez Cordellat⁴, Juan José Lerma Garrido⁴ and Cristina Campos Fernández⁵, ¹Hospital General Universitario, Valencia, Spain, ²Hospital General de Valencia, Valencia, Spain, ³Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁵Hospital General de Valencia, Valencia
Background/Purpose: One common and clinically important form of systemic lupus erythematosus (SLE) is neuropsychiatric systemic lupus erythematosus (NPSLE). This systematic review and meta-analysis aimed to…
Abstract Number: 2390 • ACR Convergence 2025
SLE Genetic Risk Loci in the Context of Environmental Exposure: A Gene-Based Classification and Clinical Insight
Nina Oparina¹, Holme Vestin¹, Sarah Reid¹, Ahmne Sayadi¹, Maija-Leena Eloranta¹, Martina Frodlund², Karoline Lerang³, Andreas Jönsen⁴, Øyvind Molberg³, Solbritt Rantapää-Dahlqvist⁵, Anna Rudin⁶, Chrisopher Sjöwall⁷, Anders Bengtsson⁴, Lars Rönnblom¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Linkoping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁴Department of Clinical Sciences, Lund University, Lund, Sweden, ⁵Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁷Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden
Background/Purpose: Growing evidence supports the role of chemical exposures as contributors to the development of Systemic lupus erythematosus (SLE)1. Several of the gene variants associated…
Abstract Number: 2224 • ACR Convergence 2025
Failure of Steroid and Antimalarial Therapy to Normalize Placental Interferon and Angiogenic Gene Expression in SLE
Seemal Faisal¹, Alexandra Anderson², Luke Sharrock³, James Tran⁴ and Milena Vukelic⁵, ¹Louisiana State University Health Science Center New Orleans, New Orleans, ²Louisiana State University Health Science Center New Orleans, Phoenix, AZ, ³Louisiana State University Health Science Center, New Orleans, LA, ⁴Louisiana State University Health Science Center, New Orleans, ⁵Rheumatology Fellowship Program Director Louisiana State University, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with an increased risk of placental insufficiency and adverse pregnancy outcomes, even when the disease is clinically quiescent.…
Abstract Number: 2142 • ACR Convergence 2025
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Hannah Concannon¹, Jasmine Oesch², Sara Mazzarelli², Anne Fields², Keisha-Gaye O'Garo² and Rebecca Sadun³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: The transition from pediatric to adult care can pose a challenge for patients with SLE and other rheumatic diseases. These patients often face preventable…
Abstract Number: 1896 • ACR Convergence 2025
Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
Jeong Yee¹, Emily Oakes², Candace Feldman³ and Karen H. Costenbader⁴, ¹Sungkyunkwan University, Suwon, MA, South Korea, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Electronic cigarettes, or e-cigarettes, are inhalable aerosol nicotine-delivery devices increasingly used in addition or in place of cigarettes. Cigarette smoking is strongly associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].